Connect Biopharma Holdings Ltd (CNTB) is the issuer whose ordinary shares are reported in a Schedule 13G by BML Investment Partners, L.P. and Braden M Leonard. BML Investment Partners, L.P. reports beneficial ownership of 3,864,400 shares, or 6.1% of the class, with shared voting and dispositive power over those shares. Braden M Leonard reports beneficial ownership of 4,264,400 shares, or 6.77%, including 400,000 shares with sole voting and dispositive power and 3,864,400 shares with shared voting and dispositive power.
Connect Biopharma Holdings Ltd (CNTB) director Kleanthis Gabriel Xanthopoulos acquired 5,000 fully vested ordinary shares on September 30, 2026. The shares were granted under the Non-Employee Director Compensation Program in lieu of a portion of his cash compensation for 2026 annual board retainers, for director service during the third quarter of 2026. His direct holdings following the acquisition were 91,554 ordinary shares.
Connect Biopharma Holdings Ltd director Jean I. Liu acquired 8,984 fully vested ordinary shares on September 30, 2026, under her election to receive shares instead of cash compensation for her 2026 annual board retainers. The shares were granted for her director service during the third quarter of 2026, bringing her direct holdings to 20,763 ordinary shares.
Connect Biopharma Holdings Limited (CNTB) reported preliminary topline results from its global Phase 2 study of rademikibart, an add-on to standard care for acute COPD exacerbations in adults with type 2 inflammation. The randomized, placebo-controlled study enrolled 159 participants.
Through Week 4, the company reported an 81% reduction in treatment failure (p=0.0122), an 85% reduction in new moderate-to-severe exacerbations (p=0.030), and a 100% reduction in new emergency-department visits and hospital admissions for exacerbations (p=0.0137), versus placebo. A 70 mL greater FEV1 improvement versus placebo was reported at Week 4 (p=0.1607); the presentation states the key secondary Day 7 FEV1 endpoint was not significant. The company reported lower incidences of adverse and serious adverse events in the rademikibart arm and no new safety signals. The presentation also lists one death of unknown cause in that arm on Day 37, described as not related to COPD. Connect plans to engage with the FDA regarding a Phase 3 program.
Connect Biopharma Holdings Ltd (CNTB) reported preliminary topline data from its global Phase 2 Seabreeze STAT asthma trial of rademikibart as an add‑on treatment for acute exacerbations in adults and adolescents with asthma and type 2 inflammation. The randomized, double‑blind, placebo‑controlled study enrolled 160 participants, dosed once subcutaneously with 600 mg rademikibart or placebo in addition to standard of care.
Rademikibart reduced the composite treatment failure rate over 28 days by about 66% versus placebo, but the primary endpoint did not reach statistical significance (p=0.153) because overall event rates were much lower than projected. The key secondary endpoint showed a statistically significant improvement in lung function: mean post‑bronchodilator FEV1 increased 250 mL with rademikibart versus 120 mL with placebo at Day 7 (130 mL difference; p=0.023), with significance also at Day 28. Rademikibart was described as well tolerated, with low adverse‑event incidence and 1 serious adverse event versus 3 on placebo.
Connect Biopharma plans to report topline data from a Phase 2 COPD exacerbation study of rademikibart later in the month and then seek FDA alignment on a Phase 3 program. The company also highlights a large addressable market with low biologic use in asthma and notes up to $99 million in remaining potential milestones plus tiered royalties from its Greater China license partner.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of Connect Biopharma Holdings Limited Ordinary Shares on a Schedule 13G/A. Through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, they report beneficial ownership of 4,338,534 Ordinary Shares, representing 6.9% of the class.
The percentage is based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. Ikarian Capital, as investment manager and sub-adviser, and Mr. Shahrestani, as its indirect controlling person, may be deemed to share voting and dispositive power over these shares, but each Reporting Person expressly disclaims beneficial ownership and membership in any group beyond what may be deemed under Section 13(d) or 13(g).
Connect Biopharma Holdings Ltd received an amended Schedule 13G from Wei Zheng reporting a beneficial ownership position in the company’s ordinary shares. Wei Zheng reports beneficial ownership of 2,520,359 ordinary shares, representing 4% of the class, with sole voting and dispositive power over all of these shares and no shared power. The percentage is based on 62,974,309 ordinary shares outstanding as disclosed in Connect Biopharma’s Form 10-Q for the period ended June 30, 2026.
Connect Biopharma Holdings Limited, a clinical-stage company focused on asthma and COPD, reported higher collaboration revenue but larger losses for the three and six months ended June 30, 2026. License and collaboration revenue rose to $2.8 million for the quarter and $2.9 million year‑to‑date, driven mainly by a regulatory milestone from the Simcere Greater China partnership, partially offset by development cost sharing.
Research and development expense increased to $16.3 million for the quarter and $31.3 million year‑to‑date, reflecting expanded rademikibart clinical programs in acute asthma and COPD. General and administrative expense declined to $4.1 million for the quarter and $8.8 million year‑to‑date, primarily from lower professional fees.
The company recorded a net loss of $17.3 million for the quarter and $36.7 million for the first half of 2026, with operating cash outflows of $31.9 million. Cash, cash equivalents and short‑term investments totaled $31.5 million as of June 30, 2026, including net proceeds of $18.6 million from a March 2026 private placement of 6,130,000 ordinary shares. Management believes these resources will meet anticipated cash requirements for at least one year from the report filing date.
Connect Biopharma Holdings Limited reported second-quarter 2026 results and clinical progress for rademikibart in asthma and COPD. Enrollment was completed in the Phase 2 Seabreeze STAT asthma and COPD studies, with topline data expected in September 2026, and a new Phase 2 Seabreeze STAT IV study was initiated in August 2026.
For the quarter ended June 30, 2026, license and collaboration revenues were $2.8 million, largely from a regulatory milestone under the Simcere license, versus $48,000 a year earlier. Research and development expense rose to $16.3 million, and general and administrative expense was $4.1 million. Net loss was $17.3 million, or ($0.27) per share, compared with $12.9 million, or ($0.23) per share, in 2025.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled $31.5 million, and the company believes this will fund operations for at least one year from the release date. Under its Simcere agreement, Connect remains eligible for up to approximately $99 million in additional milestone payments plus tiered royalties on Greater China net sales.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 3,738 Ordinary Shares of the company on June 30, 2026. These fully vested shares were issued at no cash cost to him in lieu of a portion of his 2026 annual board cash retainers for service during the second quarter of 2026.
After this equity award, he directly holds 86,554 Ordinary Shares of Connect Biopharma. The number of shares granted was determined by dividing the elected cash amount by the average closing price of the company’s ordinary shares over the 30 days preceding June 30, 2026, rounded down to the nearest whole share.